Literature DB >> 22265702

Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.

Sarah E Rotschafer1, Michael S Trujillo, Lorraine E Dansie, Iryna M Ethell, Khaleel A Razak.   

Abstract

Fragile X Syndrome (FXS) is the most common inherited form of intellectual disability, with behaviors characteristic of autism. Symptoms include abnormal social behavior, repetitive behavior, communication disorders, and seizures. Many symptoms of FXS have been replicated in the Fmr1 knockout (KO) mice. Whether Fmr1 KO mice exhibit vocal communication deficits is not known. By recording ultrasonic vocalizations (USV) produced by adult male mice during mating, we show that USV calling rate (number of calls/second) is reduced in Fmr1 KO mice compared to WT controls. The WT control and Fmr1 KO groups did not differ in other aspects of mating behavior such as time spent sniffing, mounting, rooting and without contact. Acoustic properties of calls such as mean frequency (in kHz), duration and dynamic range of frequencies were not different. This indicates a specific deficit in USV calling rate in Fmr1 KO mice. Previous studies have shown that treatment of Fmr1 KO mice with minocycline for 4weeks from birth can alleviate some behavioral symptoms. Here we tested if minocycline also reversed vocalization deficits in these mice. Calling rate increased and was similar to WT controls in adult Fmr1 KO mice treated with minocycline for four weeks from birth (P0-P28). All acoustic properties measured were similar in treated and untreated WT control mice indicating minocycline effects were specific to vocalizations in the Fmr1 KO mice. These data suggest that mating-related USVs are robust and relevant biomarkers of FXS, and that minocycline treatment is a promising avenue for treatment of FXS symptoms.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22265702     DOI: 10.1016/j.brainres.2011.12.041

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  45 in total

Review 1.  Drug discovery for autism spectrum disorder: challenges and opportunities.

Authors:  Anirvan Ghosh; Aubin Michalon; Lothar Lindemann; Paulo Fontoura; Luca Santarelli
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

2.  Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome.

Authors:  Jonathan W Lovelace; Maham Rais; Arnold R Palacios; Xinghao S Shuai; Steven Bishay; Otilia Popa; Patricia S Pirbhoy; Devin K Binder; David L Nelson; Iryna M Ethell; Khaleel A Razak
Journal:  Cereb Cortex       Date:  2020-03-14       Impact factor: 5.357

Review 3.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 4.  Progress toward treatments for synaptic defects in autism.

Authors:  Richard Delorme; Elodie Ey; Roberto Toro; Marion Leboyer; Christopher Gillberg; Thomas Bourgeron
Journal:  Nat Med       Date:  2013-06-06       Impact factor: 53.440

Review 5.  Neuroimaging endophenotypes in animal models of autism spectrum disorders: lost or found in translation?

Authors:  Marija M Petrinovic; Basil Künnecke
Journal:  Psychopharmacology (Berl)       Date:  2013-07-14       Impact factor: 4.530

Review 6.  Using mouse models of autism spectrum disorders to study the neurotoxicology of gene-environment interactions.

Authors:  Jared J Schwartzer; Claire M Koenig; Robert F Berman
Journal:  Neurotoxicol Teratol       Date:  2012-09-07       Impact factor: 3.763

Review 7.  The molecular basis of cognitive deficits in pervasive developmental disorders.

Authors:  Aditi Bhattacharya; Eric Klann
Journal:  Learn Mem       Date:  2012-08-16       Impact factor: 2.460

8.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

9.  Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.

Authors:  Harpreet Sidhu; Lorraine E Dansie; Peter W Hickmott; Douglas W Ethell; Iryna M Ethell
Journal:  J Neurosci       Date:  2014-07-23       Impact factor: 6.167

Review 10.  From FMRP function to potential therapies for fragile X syndrome.

Authors:  Ferzin Sethna; Changjong Moon; Hongbing Wang
Journal:  Neurochem Res       Date:  2013-12-18       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.